Close Menu

NEW YORK – UK-based Hemogenyx Pharmaceuticals has inked a research agreement with the University of Pennsylvania for its CAR T-cell therapy for acute myeloid leukemia.

The agreement will enable the company to conduct key proof-of-concept studies for its HEMO-CAR-T product in AML. Saar Gill, co-director of the cell therapy and transplantation program at UPenn, will be principal investigator.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.